Agenda

A focus on bladder, kidney and prostate cancers.

The World GU agenda is presented by multidisciplinary thought leaders who will present the latest insights, debate hot topics, and participate in panel discussions and audience Q&As. Attendees receive up to 11.75 CE credits.

Thursday | August 21

Poster Session & Welcome Reception

Friday | August 22

Breakfast

MDT Advancements in Staging and Treatment Planning in GU Cancers

CHAIR: Ashley Ross, MD, PhD (Northwestern Medicine)

Theranostics in Prostate: Critical Role of Imaging

Heather Jacene, MD (Brigham and Women's Hospital) & Kerry Schaffer, MD (Vanderbilt University Medical Center)

Panel Discussion

How Do You Define Locally Advanced Bladder Cancer?

Michael Woods, MD (Loyola University) & Matthew Milowksy, MD (University of North Carolina)

Panel Discussion

Diagnosis and Management of Indeterminant Metastasis in Kidney Cancer

Brian Shuch, MD (University of California Los Angeles) & Rajan Gupta, MD (Duke Cancer Center)

Panel Discussion and Q&A

Networking Break

Managing Early-Stage Disease

CHAIR: Stacy Loeb, MD (NYU Langone Health & Manhattan VA)

Early-Stage Kidney: Surgery, Ablation and Active Surveillance

Phillip Pierorazio, MD (University of Pennsylvania)

Early-Stage Bladder: The Evolving Landscape

Sam Chang, MD, MBA (Vanderbilt University Medical Center)

Early-Stage Prostate: Novel Diagnostics, Focal Therapy and Active Surveillance

Daniel Barocas, MD (Vanderbilt University Medical Center)

Radiation Chip Shots: Small Tumors and Localized Disease

Eric Shinohara, MD (Vanderbilt University Medical Center)

Panel Discussion and Q&A

Mark Fleming, MD (Virginia Oncology Associates)

Lunch Symposium (Non-CE)

Multidisciplinary Care of High-Risk Patients in GU Cancers

CHAIR: Karen Hoffman, MD, MHSc, MPH, FASTRO

High-Risk Kidney Cancer

Naomi Haas, MD (University of Pennsylvania) & Michael Abern, MD (Duke Cancer Center)

Panel Discussion

High-Risk Prostate Cancer

James Eastham, MD (Memorial Sloan Kettering Cancer Center) & Jonathan Leeman, MD (Harvard Medical School)

Panel Discussion and Q&A

High-Risk Bladder Cancer

Jason Efstathiou, MD, DPHIL (Massachusetts General Hospital) & Monika Joshi, MD (Penn State Cancer Institute)

Panel Discussion and Q&A

Networking Break

Case-Based Real-World Management and Therapeutic Interventions in GU Cancers- Part I: Maximizing MDT Resources

CHAIR: Mehmet Bilen, MD (Winship Cancer Institute of Emory University)

Case-Based Approach to Oligometastatic Renal Disease

Michael Harrison, MD (Duke Cancer Center)

Case-Based Approach to Locally Advanced Bladder Cancer

Kristin Scarpato, MD (Vanderbilt University Medical Center)

The Current State of mHSPC: Volume of Disease and Treatment Management

Elizabeth Kessler, MD (University of Colorado Health)

Risk Stratification and Future Developments in Precison Management of Prostate Cancer

Mutlay Sayan, MD (Harvard Medical School)

Panel Discussion and Q&A

Classifying and Managing Rare Histologies Across GU Cancers

CHAIR: Manojkumar Bupathi, MD (Rocky Mountain Cancer Center)

Classifying Rare Histologies

Jiaoti Huang, MD, PhD (Duke Cancer Center)

How do you Manage Rare Bladder Histologies?

Arlene Siefker-Radtke, MD (MD Anderson Cancer Center)

Managing Upper Tract Urothelial Carcinoma

Jeannie Hoffman-Censits, MD (Johns Hopkins Kimmel Cancer Center)

Management of Rare Kidney Histologies

Darren Feldman, MD (Memorial Sloan Kettering Cancer Center)

Panel Discussion and Q&A

Bradley Somer, MD (West Cancer Center & Research Institute)

Keynote Presentation (Non-CE)

Chaunté Lowe

4x Olympian
Founder & CEO
Boundless Resilience

Saturday | August 23

Breakfast

Tools for Tomorrow's Oncologist

CHAIR: Katy Beckermann, MD, PhD (Tennessee Oncology)

Role of Precision Medicine

Ulka Vaishampayan, MD (University of Michigan)

Trials in Progress in Early-Stage Therapeutics

Elisabeth Heath, MD (Mayo Clinic)

Patient Frailty/FIT Levels

Stephanie Berg, DO (Harvard Medical School)

Palliative Care & Decision Making

Elizabeth Wulff-Burchfield, MD (University of Kansas)

Implementing Pathways in an Evolving Landscape

Lisa Raff, PharmD (OneOncology)

Improving Communication in a Multidisciplinary Environment

Kelvin Moses, MD, PhD (Vanderbilt University Medical Center)

Q&A

Networking Break

Strategies for the Implementation of MRD in GU Cancers

CHAIR: Benjamin Maughan, MD (Huntsman Cancer Institute)

Defining MRD

Alan Tan, MD (Vanderbilt University Medical Center)

Using ctDNA to measure MRD in Bladder Cancer

Elizabeth Plimack, MD (Fox Chase Cancer Center)

What's Different with MRD in Prostate?

Michael Schweizer, MD (Fred Hutch Cancer Center)

Controversies in Imaging MRD: PSMA PET and Biochemical Recurrence

Ravi Madan, MD (National Institutes of Health)

How Can We Better Measure MRD in Kidney?

Brian Rini, MD (Vanderbilt University Medical Center)

Panel Discussion and Q&A

Jeffrey Yorio, MD (Texas Oncology)

Special Session

Introduction

Daniel George, MD (Duke Cancer Center) & Alicia Morgans, MD, MPH, FASCO (Harvard Medical School)

Fireside Chat with Robert Califf, MD, MACC, former FDA Commissioner

Robert Califf, MD, MACC (Duke University Medical Center)

Lunch Symposium (Non-CE)

Case-Based Real-World Management and Therapeutic Interventions in GU Cancers- Part 2

CHAIR: Edwin Posadas, MD (Cedars Sinai Medical Center)

Case-Based Approach to PARP Inhibitors in Prostate Cancer

Chandler Park, MD (Norton Healthcare)

Case-Based Approach to Kidney Cancer

Hans Hammers, MD, PhD (UT Southwestern)

Bladder MIBC Systemic Therapy and Outcomes

Jacqueline Brown, MD (Winship Cancer Institute of Emory University)

Panel Discussion and Q&A

Michael Lattanzi, MD (Texas Oncology)

Early-Stage Therapeutics: New Drugs in the Contemporary Landscape

CHAIR: Robert Dreicer, MD (University of Virginia)

Emerging Approaches to Bladder Cancer

Karine Tawagi, MD (University of Illinois at Chicago)

Emerging Approaches to Prostate Cancer

Benjamin Garmezy, MD (Sarah Cannon Research Institute)

Emerging Approaches to Kidney Cancer

Eric Jonasch, MD (MD Anderson Cancer Center)

Harnessing Resistance to Immunotherapy Approaches in Kidney Cancer

David Braun, MD, PhD (Yale Medicine)

Q&A

Networking Break

Applying the Good News into Everyday Practice

CHAIRS: Charles Ryan, MD (Memorial Sloan Kettering Cancer Center) & Alicia Morgans, MD, MPH, FASCO (Harvard Medical School)

Monday Morning Quick Start

World GU-Pardy

HOST: Mark Pomerantz, MD (Harvard Medical School)

Farewell Reception

Let's join the biggest marketing conference on 2022.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.